Nina Magnolo

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L. Simpson, Rodney Sinclair, Seth Forman et al. · The Lancet · 2020 · 452 citations · Full text

Allergy, Atopic Dermatitis, Medicine +9

Trial of Intravenous Immune Globulin in Dermatomyositis

Rohit Aggarwal, Christina Charles‐Schoeman, Joachim Schessl et al. · New England Journal of Medicine · 2022 · 181 citations · Full text

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials

Jonathan I. Silverberg, Andreas Wollenberg, Adam Reich et al. · The Lancet · 2024 · 85 citations

Allergy, Atopic Dermatitis, Allergy Medicine +8

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter et al. · The Lancet · 2023 · 63 citations

Tumor Immunology, Surgical Oncology, Nivolumab Versus Observation +10